OTLK (Outlook Therapeutics) EV-to-EBIT : 8.01 (As of May. 02, 2025)

Outlook Therapeutics EV-to-EBIT Chart

Outlook Therapeutics Annual Data
	Trend	Sep15	Sep16	Sep17	Sep18	Sep19	Sep20	Sep21	Sep22	Sep23	Sep24
EV-to-EBIT		Get a 7-Day Free Trial					-2.39	-7.28	-4.20	-1.23	-1.97

Outlook Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EV-to-EBIT	Get a 7-Day Free Trial															-2.53	-4.14	80.48	-1.97	7.58

Competitive Comparison of Outlook Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Outlook Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Outlook Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's EV-to-EBIT falls into.

Outlook Therapeutics EV-to-EBIT Calculation

Outlook Therapeutics's EV-to-EBIT for today is calculated as:

Outlook Therapeutics's current Enterprise Value is $76.54 Mil.
Outlook Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics  (NAS:OTLK) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Outlook Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Outlook Therapeutics's Enterprise Value for the quarter that ended in Dec. 2024 was $72.40 Mil.
Outlook Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics Business Description